REN and familial dilated cardiomyopathy: Female DCM mice were randomized to begin treatment at 50 days when pathologically elevated plasma renin activity concentration is first detected and there is an initial decline in EF corresponding to Stage B HF (Figure 1a) without the onset of edema and elevation of ANP/BNP plasma biomarkers [27,32].